Anvisa promove Seminário de Inovação e Design Thinking
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3764231
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3764231
The European Medicines Agency (EMA) has launched today a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new system makes it easier for marketing authorisation holders and sponsors of clinical trials to report suspected adverse reactions and allows for better analysis of this information for the benefit of patient safety in Europe.
For more information go to EudraVigilance
RT @WHO: "#ClimateChange takes an ever-increasing toll on health, especially for people in small island developing states (#SIDS)"—@DrTedro…
RT @WHO: Every 20 minutes:
670 people die from cardiovascular disease
335 people die from cancer
200 young children die from preventable ca…
RT @WHO: "People today live longer than at any time in human history."—@DrTedros #EBSS4
Full speech 📄 bit.ly/2Am4v2J https://t.co/…
RT @WHO: "To address the new global health challenges, we cannot do business as usual. We need a paradigm shift, a radical change in approa…
RT @WHO: "In addition to changing disease patterns & geopolitical shifts, the #GlobalHealth architecture has changed dramatically. So must…